Kane Biotech Inc. (CVE:KNE) Director Purchases C$200,000.00 in Stock

Kane Biotech Inc. (CVE:KNE) Director Marc Edwards purchased 2,000,000 shares of the company’s stock in a transaction dated Friday, January 17th. The shares were purchased at an average cost of C$0.10 per share, for a total transaction of C$200,000.00.

Kane Biotech Price Performance

CVE:KNE remained flat at C$0.11 during mid-day trading on Thursday. 22,500 shares of the company were exchanged, compared to its average volume of 97,861. The company has a debt-to-equity ratio of 1,164.24, a current ratio of 0.82 and a quick ratio of 0.39. Kane Biotech Inc. has a 52 week low of C$0.08 and a 52 week high of C$0.17. The business’s 50-day simple moving average is C$0.11 and its two-hundred day simple moving average is C$0.13. The stock has a market capitalization of C$14.58 million, a price-to-earnings ratio of -3.67 and a beta of 0.52.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.